CN112566650A - 异二聚体蛋白及其用途 - Google Patents

异二聚体蛋白及其用途 Download PDF

Info

Publication number
CN112566650A
CN112566650A CN201980053803.4A CN201980053803A CN112566650A CN 112566650 A CN112566650 A CN 112566650A CN 201980053803 A CN201980053803 A CN 201980053803A CN 112566650 A CN112566650 A CN 112566650A
Authority
CN
China
Prior art keywords
protein
ser
amino acid
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980053803.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·施赖伯
G·弗罗姆
S·达西瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of CN112566650A publication Critical patent/CN112566650A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980053803.4A 2018-06-21 2019-06-21 异二聚体蛋白及其用途 Pending CN112566650A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862688167P 2018-06-21 2018-06-21
US62/688,167 2018-06-21
US201862703248P 2018-07-25 2018-07-25
US62/703,248 2018-07-25
PCT/US2019/038451 WO2019246508A1 (en) 2018-06-21 2019-06-21 Heterodimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
CN112566650A true CN112566650A (zh) 2021-03-26

Family

ID=68983045

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053803.4A Pending CN112566650A (zh) 2018-06-21 2019-06-21 异二聚体蛋白及其用途

Country Status (10)

Country Link
US (3) US10995127B2 (https=)
EP (1) EP3810172A4 (https=)
JP (3) JP7439372B2 (https=)
KR (1) KR20210025054A (https=)
CN (1) CN112566650A (https=)
AU (1) AU2019290192A1 (https=)
BR (1) BR112020026112A2 (https=)
CA (1) CA3103975A1 (https=)
MX (1) MX2020014031A (https=)
WO (1) WO2019246508A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140436A1 (zh) * 2023-12-27 2025-07-03 上海药明生物技术有限公司 重组il-27蛋白及其制备方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
AU2020340424A1 (en) * 2019-08-30 2022-03-31 Shattuck Labs, Inc. Chimeric proteins in autoimmunity
WO2021202354A1 (en) * 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2022241058A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
WO2023205738A2 (en) * 2022-04-20 2023-10-26 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
CA3256783A1 (en) 2022-05-16 2023-11-23 Enkefalos Biosciences, Llc Blood-brain barrier translocation peptides and associated molecules and their methods of use
WO2024019984A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof
EP4619430A1 (en) 2022-11-16 2025-09-24 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025133115A1 (en) * 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用
US20260035414A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012345A2 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
CN1382158A (zh) * 1999-08-09 2002-11-27 利思进药品公司 多细胞因子－抗体复合物
US20020193570A1 (en) * 1997-12-08 2002-12-19 Gillies Stephen D. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20060009501A1 (en) * 2004-07-09 2006-01-12 Nair P K R Materials and methods for immune system stimulation
WO2009080816A1 (en) * 2007-12-21 2009-07-02 Altonabiotec Ag Fusion polypeptides comprising a shbg dimerization component and uses thereof
US20170095531A1 (en) * 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CN107001485A (zh) * 2014-11-24 2017-08-01 苏州丁孚靶点生物技术有限公司 蛋白质异二聚体及其用途
CN107531805A (zh) * 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
CA3054133A1 (en) * 2017-02-27 2018-03-30 Shattuck Labs, Inc. Methods of making and using extracellular domain-based chimeric proteins
WO2018064190A1 (en) * 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
WO2018067991A1 (en) * 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN107922493A (zh) * 2015-07-26 2018-04-17 分子模板公司 包含志贺毒素a亚基效应物和cd8+ t‑细胞表位的细胞靶向分子

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196297T1 (de) * 1994-05-18 2000-09-15 Synthetic Peptides Inc Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung
IT1274350B (it) * 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
ATE295887T1 (de) 1996-02-20 2005-06-15 Applied Research Systems Heterodimerebildende hybrid-proteine
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
KR20120108967A (ko) * 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2902739C (en) * 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
US10017545B2 (en) * 2013-06-03 2018-07-10 University Of Maryland, College Park Compositions and vaccines comprising vesicles and methods of using the same
HK1243629A1 (zh) 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
AU2020340424A1 (en) * 2019-08-30 2022-03-31 Shattuck Labs, Inc. Chimeric proteins in autoimmunity

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193570A1 (en) * 1997-12-08 2002-12-19 Gillies Stephen D. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
CN1382158A (zh) * 1999-08-09 2002-11-27 利思进药品公司 多细胞因子－抗体复合物
WO2002012345A2 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
US20060009501A1 (en) * 2004-07-09 2006-01-12 Nair P K R Materials and methods for immune system stimulation
WO2009080816A1 (en) * 2007-12-21 2009-07-02 Altonabiotec Ag Fusion polypeptides comprising a shbg dimerization component and uses thereof
CN107001485A (zh) * 2014-11-24 2017-08-01 苏州丁孚靶点生物技术有限公司 蛋白质异二聚体及其用途
CN107531805A (zh) * 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
CN107922493A (zh) * 2015-07-26 2018-04-17 分子模板公司 包含志贺毒素a亚基效应物和cd8+ t‑细胞表位的细胞靶向分子
US20170095531A1 (en) * 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2018064190A1 (en) * 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
WO2018067991A1 (en) * 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CA3054133A1 (en) * 2017-02-27 2018-03-30 Shattuck Labs, Inc. Methods of making and using extracellular domain-based chimeric proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140436A1 (zh) * 2023-12-27 2025-07-03 上海药明生物技术有限公司 重组il-27蛋白及其制备方法

Also Published As

Publication number Publication date
JP7452932B2 (ja) 2024-03-19
WO2019246508A1 (en) 2019-12-26
MX2020014031A (es) 2021-05-12
AU2019290192A1 (en) 2021-01-07
JP2021527700A (ja) 2021-10-14
JP2024057087A (ja) 2024-04-23
CA3103975A1 (en) 2019-12-26
JP2023116718A (ja) 2023-08-22
US10995127B2 (en) 2021-05-04
EP3810172A4 (en) 2022-04-20
US20200079831A1 (en) 2020-03-12
EP3810172A1 (en) 2021-04-28
KR20210025054A (ko) 2021-03-08
US11780897B2 (en) 2023-10-10
BR112020026112A2 (pt) 2021-04-06
US20230220030A1 (en) 2023-07-13
US20210214409A1 (en) 2021-07-15
JP7439372B2 (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7452932B2 (ja) ヘテロ二量体タンパク質及びその使用
JP7620045B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
EP4183451B1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
RU2775490C2 (ru) Химерные белки на основе tigit и light
HK40091905A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
HK40092182A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210326

RJ01 Rejection of invention patent application after publication